These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3998766)

  • 1. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer.
    Schulof RS; Lloyd MJ; Cleary PA; Palaszynski SR; Mai DA; Cox JW; Alabaster O; Goldstein AL
    J Biol Response Mod; 1985 Apr; 4(2):147-58. PubMed ID: 3998766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell abnormalities after mediastinal irradiation for lung cancer. The in vitro influence of synthetic thymosin alpha-1.
    Schulof RS; Chorba TL; Cleary PA; Palaszynski SR; Alabaster O; Goldstein AL
    Cancer; 1985 Mar; 55(5):974-83. PubMed ID: 3155644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of thymosin fraction 5 and thymosin alpha 1.
    Dillman RO; Beauregard J; Royston I; Zavanelli MI
    J Biol Response Mod; 1987 Jun; 6(3):263-7. PubMed ID: 3598602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer.
    Scher HI; Shank B; Chapman R; Geller N; Pinsky C; Gralla R; Kelsen D; Bosl G; Golbey R; Petroni G
    Cancer Res; 1988 Mar; 48(6):1663-70. PubMed ID: 2830968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects.
    Schulof RS; Simon GL; Sztein MB; Parenti DM; DiGioia RA; Courtless JW; Orenstein JM; Kessler CM; Kind PD; Schlesselman S
    J Biol Response Mod; 1986 Oct; 5(5):429-43. PubMed ID: 3490545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy.
    Chretien PB; Lipson SD; Makuch R; Kenady DE; Cohen MH; Minna JD
    Cancer Treat Rep; 1978 Nov; 62(11):1787-90. PubMed ID: 215307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of thymosin fraction 5 in advanced renal cancer.
    Schulof RS; Lloyd MJ; Ueno WM; Green LD; Stallings JJ
    J Biol Response Mod; 1984; 3(2):151-9. PubMed ID: 6610022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression and reconstitution with thymosin after radiation therapy.
    Wara WM; Wara DW; Ammann AJ; Barnard JL; Phillips TL
    Int J Radiat Oncol Biol Phys; 1979 Jul; 5(7):997-1001. PubMed ID: 511632
    [No Abstract]   [Full Text] [Related]  

  • 9. In vivo immune restoration in advanced cancer patients after administration of thymosin fraction 5 or thymosin alpha 1.
    Dillman RO; Beauregard JC; Zavanelli MI; Halliburton BL; Wormsley S; Royston I
    J Biol Response Mod; 1983; 2(2):139-49. PubMed ID: 6315897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymosin alpha-1 as adjunct for conventional therapy of malignant tumors: a review.
    Bepler G
    Cancer Invest; 1994; 12(5):491-6. PubMed ID: 7922706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell levels and response to thymosin in vitro during intensive chemotherapy in cancer patients receiving thymosin.
    Goldberg NH; Lipson SD; Kenady DE; Simon RM; Cohen MH; Chretien PB
    Surg Forum; 1977; 28():151-2. PubMed ID: 214880
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prevention and management of lung infections with thymosin alpha1 in critical patients with tracheotomy].
    Huang DP; Yang M; Peng WP; Chen XS; Chen ZQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):128-9. PubMed ID: 16495194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study.
    Wang X; Li W; Niu C; Pan L; Li N; Li J
    Inflammation; 2011 Jun; 34(3):198-202. PubMed ID: 20549321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymosin fraction 5 does not accelerate reconstitution of immunologic reactivity after human marrow grafting.
    Witherspoon RP; Hersman J; Storb R; Ochs H; Goldstein AL; McClure J; Noel D; Weiden PL; Thomas ED
    Br J Haematol; 1983 Dec; 55(4):595-608. PubMed ID: 6367801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Modulation with Thymosin Alpha 1 Treatment.
    King R; Tuthill C
    Vitam Horm; 2016; 102():151-78. PubMed ID: 27450734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstitution of T cell functions in aging mice by thymosin alpha 1.
    Frasca D; Adorini L; Mancini C; Doria G
    Immunopharmacology; 1986 Jun; 11(3):155-63. PubMed ID: 2942521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal lymphangiectasia and thymic hypoplasia.
    Sorensen RU; Halpin TC; Abramowsky CR; Hornick DL; Miller KM; Naylor P; Incefy GS
    Clin Exp Immunol; 1985 Jan; 59(1):217-26. PubMed ID: 3971596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymosin α 1: a novel therapeutic option for patients with refractory chronic purulent rhinosinusitis.
    Dalm VA; de Wit H; Drexhage HA
    Ann N Y Acad Sci; 2012 Oct; 1270():1-7. PubMed ID: 23050810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot clinical trial of the toxicity and immunorestorative effects of T cell reconstituting factor (SR 270258) in immunosuppressed cancer patients.
    Murray JL; Reuben JM; Smith TL; Gehan EA; Koretz SM; Hersh EM
    J Biol Response Mod; 1987 Feb; 6(1):56-68. PubMed ID: 2951501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis.
    King RS; Tuthill C
    Expert Opin Biol Ther; 2015; 15 Suppl 1():S41-9. PubMed ID: 25643200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.